DexCom, Inc. (DXCM) Stock

About DexCom, Inc.

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

DexCom, Inc. is led by CEO Jacob Steven Leach, employs 10,200 people, headquartered in San Diego, US, publicly traded since 2005.

DexCom, Inc. (DXCM) stock trades at $73.51 with a market capitalization of $28.37B. The stock is valued at a price-to-earnings (P/E) ratio of 26.01, price-to-book of 7.91, price-to-sales of 5.86. Over the past 52 weeks the stock has ranged between $54.11 and $89.98, and currently trades 18.3% below its 52-week high.

On profitability, DexCom, Inc. generates a return on equity (ROE) of 35.62% — well above the market average, a sign of a high-quality business, return on capital employed of 33.21%, an operating margin of 19.56%, a net profit margin of 19.31%.

In its most recent fiscal year, DexCom, Inc. reported annual revenue of $4.7B, net profit of $836.0M, revenue has compounded at 19.3% a year over the last five years, profit at 11.1% a year.

The balance sheet shows a debt-to-equity ratio of 0.47 — a conservative balance sheet with little leverage risk, a current ratio of 1.88, total assets of $6.3B, $918.0M in cash and equivalents.

DXCM has an average daily trading volume of 5,735,137 shares, a beta of 1.44 (more volatile than the overall market).

Official website: www.dexcom.com